Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Cited by (7,578)

Items 701–800 of 7,578

1. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
   Na Wang, Chun Zhang · 2024 · International Journal of Molecular Sciences
2. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
   Sankar Dass Navaneethan, Nisha Bansal, Kerri L. Cavanaugh, Alex R. Chang, Susan T. Crowley, Cynthia Delgado, Michelle M. Estrella, Cybele Ghossein, Talat Alp Ikizler, Holly M. Koncicki et al. · 2024 · American Journal of Kidney Diseases
3. Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate
   Amir M. Al Hroob, Mohammad H. Abukhalil, Omnia E. Hussein, Ayman Moawad Mahmoud · 2018 · Biomedicine & Pharmacotherapy
4. Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis
   Khera, Rohan, Pandey, Ambarish, Chandar, Apoorva K., Murad, Mohammad H., Prokop, Larry J., Neeland, Ian J., Berry, Jarett D., Camilleri, Michael, Singh, Siddharth · 2018 · Gastroenterology
5. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
   Nauck, Michael A., Jensen, Thomas Jon, Rosenkilde, Carina, Calanna, Salvatore, Buse, John B., the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2018 · Diabetes Care
6. The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
   Jonathan D. Newman, Anish K. Vani, José O. Alemán, HOWARD S. WEINTRAUB, Jeffrey S. Berger, Arthur Z. Schwartzbard · 2018 · Journal of the American College of Cardiology
7. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
   Bohula, Erin A, Scirica, Benjamin M, Inzucchi, Silvio E, McGuire, Darren K, Keech, Anthony C, Smith, Steven R, Kanevsky, Estella, Murphy, Sabina A, Leiter, Lawrence A, Dwyer, Jamie P et al. · 2018 · The Lancet
8. Structural insights into probe-dependent positive allosterism of the GLP-1 receptor
   Ana Belen Bueno, Bingfa Sun, Francis S. Willard, Dan Feng, Joseph D. Ho, David B. Wainscott, Aaron D. Showalter, Michal Vieth, Qi Chen, Cynthia Stutsman et al. · 2020 · Nature Chemical Biology
9. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
   Clara García-Carro, Ander Vergara, Sheila Bermejo, Maria Antonieta Azancot, Joana Sellarés, María José Soler · 2021 · Frontiers in Medicine
10. Semaglutide: review and place in therapy for adults with type 2 diabetes
    Goldenberg, Ronald M., Steen, Oren · 2019 · Canadian Journal of Diabetes
11. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis
    Myasoedova, Veronika A., Parisi, Valentina, Moschetta, Donato, Valerio, Vincenza, Conte, Maddalena, Massaiu, Ilaria, Bozzi, Michele, Celeste, Fabrizio, Leosco, Dario, Iaccarino, Guido et al. · 2023 · Cardiovascular Diabetology
12. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
    Bart Staels · 2017 · The American Journal of Medicine
13. The Impact of Glycated Hemoglobin (HbA1c) on Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank
    Shiu Lun Au Yeung, Shan Luo, Catherine Mary Schooling · 2018 · Diabetes Care
14. Modern pharmacological treatment of obese patients
    Marcus May, Christoph Schindler, Stefan Engeli · 2020 · Therapeutic Advances in Endocrinology and Metabolism
15. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
    Chintan V. Dave, Seoyoung C. Kim, Allison B. Goldfine, Robert J. Glynn, Angela Tong, Elisabetta Patorno · 2020 · Circulation
16. Technology in the management of type 2 diabetes: Present status and future prospects
    AIDEEN B. DALY, Roman Hovorka · 2021 · Diabetes Obesity and Metabolism
17. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
    Marine Monney, François R. Jornayvaz, Karim Gariani · 2023 · Diabetes & Metabolism
18. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
    Layla A. Abushamat, Pir Ahmad Shah, Robert H. Eckel, Stephen A. Harrison, Diana Barb · 2024 · Clinical Gastroenterology and Hepatology
19. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity
    Matthew M.Y. Lee, Nazim Ghouri, Anoop Misra, Yu Mi Kang, Martin K. Rutter, Hertzel C. Gerstein, Darren K. McGuire, Naveed A. Sattar · 2025 · Diabetes Care
20. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
    Mattía Galli, Stefano Benenati, Claudio Laudani, Beatrice Simeone, Gianmarco Sarto, Luis Ortega‐Paz, Erica Rocco, Marco Bernardi, Luigi Spadafora, Domenico D’Amario et al. · 2025 · Journal of the American College of Cardiology
21. Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
    Goldenberg, Ronald M., Cheng, Alice Y.Y., Fitzpatrick, Tess, Gilbert, Jeremy D., Verma, Subodh, Hopyan, Julia J. · 2022 · Stroke
22. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
    Seminer, Allie, Mulihano, Alfredi, O’Brien, Clare, Krewer, Finn, Costello, Maria, Judge, Conor, O’Donnell, Martin, Reddin, Catriona · 2025 · JAMA Neurology
23. Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer
    Sinclair, Piriyah, Brennan, Donal J., le Roux, Carel W. · 2018 · Nature Reviews Gastroenterology & Hepatology
24. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
    David E. Kloecker, Melanie Jane Davies, Kamlesh Khunti, Francesco Zaccardi · 2020 · Annals of Internal Medicine
25. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
    Lim, Lee-Ling, Chow, Elaine, Chan, Juliana C. N. · 2023 · Nature Reviews Endocrinology
26. Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
    Erin D. Michos, Francisco Alejandro López-Jiménez, Martha Gulati · 2023 · Journal of the American Heart Association
27. The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs
    Michał Nicze, Maciej Borówka, Adrianna Dec, Aleksandra Niemiec, Łukasz Bułdak, Bogusław Okopień · 2024 · International Journal of Molecular Sciences
28. Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
    David Bode, Julius Ryan D. Pronto, Gabriele G. Schiattarella, Niels Voigt · 2024 · Nature Reviews Cardiology
29. Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets
    Ioannis Akoumianakis, Akansha Tarun, Charalambos A. Antoniades · 2016 · British Journal of Pharmacology
30. Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?
    Hanssen, Nordin M. J., Kraakman, Michael J., Flynn, Michelle C., Nagareddy, Prabhakara R., Schalkwijk, Casper G., Murphy, Andrew J. · 2020 · Frontiers in Cardiovascular Medicine
31. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis
    Chiang, Cho-Hung, Jaroenlapnopparat, Aunchalee, Colak, Sena Cakir, Yu, Chun-Chiao, Xanthavanij, Nutchapon, Wang, Tsu-Hsien, See, Xin Ya, Lo, Shao-Wei, Ko, Albert, Chang, Yu-Cheng et al. · 2025 · Gastroenterology
32. Newer GLP-1 receptor agonists and obesity-diabetes
    Emily E. Brown, Daniel James Cuthbertson, John P.H. Wilding · 2018 · Peptides
33. Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date
    Lavanya Athithan, Gaurav Singh Gulsin, Gerry Patrick McCann, Eylem Levelt · 2019 · World Journal of Diabetes
34. A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist
    Jee Sun Min, Seong Jun Jo, Sangyoung Lee, Duk Yeon Kim, Da Hyun Kim, Chae Bin Lee, Soo Kyung Bae · 2025 · Drug Design Development and Therapy
35. Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure
    Peter Swoboda, Adam Kenneth McDiarmid, Bara Erhayiem, David Paul Ripley, Laura Elizabeth Dobson, Pankaj Garg, Tarique A Musa, Klaus K. Witte, Mark T. Kearney, Julian H. Barth et al. · 2017 · Journal of the American Heart Association
36. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
    Marian Sue Kirkman, Hussain Mahmud, Mary T. Korytkowski · 2018 · Endocrinology and Metabolism Clinics of North America
37. Acute Coronary Syndromes and Acute Heart Failure: A Diagnostic Dilemma and High-Risk Combination. A Statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology
    Veli‐Pekka Harjola, John Parissis, Johann K Bauersachs, Hans‐Peter Brunner‐La Rocca, Héctor Bueno, Jelena Čelutkienė, Ovidiu Dragomir Chioncel, Andrew J.S. Coats, Sean P. Collins, Rudolf A. de Boer et al. · 2020 · European Journal of Heart Failure
38. Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
    Subodh Verma, Darren K. McGuire, Stephen Charles Bain, Deepak L. Bhatt, Lawrence A. Leiter, C. David Mazer, Tea Monk Fries, Richard E. Pratley, Søren Rasmussen, Hrvoje Vražić et al. · 2020 · Diabetes Obesity and Metabolism
39. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
    Rozalina G. McCoy, Holly K. Van Houten, Yihong Deng, Pinar Karaca‐Mandic, Joseph S. Ross, Víctor M. Montori, Nilay D. Shah · 2021 · JAMA Network Open
40. Diabetic heart disease: A clinical update
    Jake Rajbhandari, Cornelius James Fernandez, Mayuri Agarwal, Beverly Xin Yi Yeap, Joseph M Pappachan · 2021 · World Journal of Diabetes
41. Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application
    Mona C. Löffler, Matthias Johannes Betz, Denis P. Blondin, Robert Augustin, Anand Kumar Sharma, Yu‐Hua Tseng, Camilla Schéele, Heike Zimdahl, Michael Mark, Anita M. Hennige et al. · 2021 · Molecular Metabolism
42. Gasdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury: Cumulative evidence for future cardioprotective strategies
    Panat Yanpiset, Chayodom Maneechote, Sirawit Sriwichaiin, Natthaphat Siri‐Angkul, Siriporn Chaisin Chattipakorn, Nipon Chattipakorn · 2022 · Acta Pharmaceutica Sinica B
43. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
    Mansour A. Tobaiqy, Hajer Elkout · 2024 · International Journal of Clinical Pharmacy
44. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
    Yusuke Nakatsu, Hiroki Kokubo, Bumdelger Batmunkh, Masao Yoshizumi, Takeshi Yamamotoya, Yasuka Matsunaga, Koji Ueda, Yuki Inoue, Masakí Inoue, Midori Fujishiro et al. · 2017 · International Journal of Molecular Sciences
45. Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis
    Ioannis Avgerinos, Theodoros Michailidis, Aris Liakos, Thomas Karagiannis, David Richard Matthews, Απόστολος Τσάπας, Eleni Bekiari · 2019 · Diabetes Obesity and Metabolism
46. 2020 Clinical practice guidelines for Chronic heart failure
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
47. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
    Lyseng-Williamson, Katherine A. · 2019 · Clinical Drug Investigation
48. Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation
    Chikayo Iwaya, Takashi Nomiyama, Shiho Komatsu, Takako Kawanami, Yoko Tsutsumi, Yuriko Hamaguchi, Tsuyoshi Horikawa, Yasuteru Yoshinaga, Shin-ichi Yamashita, Tomoko Tanaka et al. · 2017 · Endocrinology
49. Treatment approach to type 2 diabetes: Past, present and future
    Kristina Blaslov, Fran Stjepan Naranđa, Ivan Kruljac, Ivana Pavlić Renar · 2018 · World Journal of Diabetes
50. Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE , LEADER and SUSTAIN ‐6 cardiovascular outcomes trials
    Anna R. Kahkoska, Milan S. Geybels, Klara Rachel Klein, Frederik Flindt Kreiner, Nikolaus Marx, Michael Albrecht Nauck, Richard E. Pratley, Benjamin Ole Wolthers, John B. Buse · 2020 · Diabetes Obesity and Metabolism
51. Management of Obesity in Cardiovascular Practice
    Després, Jean-Pierre, Carpentier, André C., Tchernof, André, Neeland, Ian J., Poirier, Paul · 2021 · Journal of the American College of Cardiology
52. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
    Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo · 2022 · Kidney Research and Clinical Practice
53. Glucocorticoids, stress and eating: The mediating role of appetite‐regulating hormones
    Susanne Kuckuck, Eline S. van der Valk, A.J.W. Scheurink, Bibian van der Voorn, Anand M. Iyer, Jenny A. Visser, Patric J. D. Delhanty, Sjoerd A.A. van den Berg, Elisabeth F. C. van Rossum · 2022 · Obesity Reviews
54. Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments
    Kazi N. Islam, Rahib K. Islam, Ivan D. Nguyen, Hassan Malik, Humza Pirzadah, Barsha Shrestha, Isabella B Lentz, Sahar Shekoohi, Alan D. Kaye · 2025 · Advances in Therapy
55. Oxyntomodulin: actions and role in diabetes
    Holst, Jens J., Albrechtsen, Nicolai J.Wewer, Gabe, Maria Buur Nordskov, Rosenkilde, Mette Marie · 2018 · Peptides
56. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
    Oellgaard, Jens, Gæde, Peter, Rossing, Peter, Rørth, Rasmus, Køber, Lars, Parving, Hans-Henrik, Pedersen, Oluf · 2018 · Diabetologia
57. First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study
    Choi, Jin G., Winn, Aaron N., Skandari, M. Reza, Franco, Melissa I., Staab, Erin M., Alexander, Jason, Wan, Wen, Zhu, Mengqi, Huang, Elbert S., Philipson, Louis et al. · 2022 · Annals of Internal Medicine
58. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
    Cristina Barale, Simona Buracco, Franco Luigi Cavalot, Chiara Frascaroli, Angelo Guerrasio, Isabella Russo · 2017 · Thrombosis and Haemostasis
59. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
    Steinberg, William M., Buse, John B., Ghorbani, Marie Louise Muus, Ørsted, David D., Nauck, Michael A., the LEADER Steering Committee, on behalf of the LEADER Trial Investigators · 2017 · Diabetes Care
60. Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes
    Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito · 2018 · Journal of Endocrinological Investigation
61. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block
    Vasilios Gabriel Athyros, Stergios A. Pοlyzos, J Kountouras, Niki Katsiki, Panagiotis G. Anagnostis, Michael N. Doumas, Christos Socrates Mantzoros · 2019 · Current Vascular Pharmacology
62. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Marco Castellana, Angelo Cignarelli, Francesco Brescia, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino · 2019 · Scientific Reports
63. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
    João Victor da Silva Guerra, Marieli M. G. Dias, Anna Julyana Viana Chianca Brilhante, Maiara Ferreira Terra, Marta García‐Arévalo, Ana Carolina Migliorini Figueira · 2021 · Nutrients
64. Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice
    Michaele B. Manigrasso, Piul S. Rabbani, Lander Egaña-Gorroño, Nosirudeen Quadri, Laura Frye, Boyan Zhou, Sergey Reverdatto, Lisa S. Ramirez, Stephen J. Dansereau, Jinhong Pan et al. · 2021 · Science Translational Medicine
65. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Arnold, Suzanne V., Tang, Fengming, Cooper, Andrew, Chen, Hungta, Gomes, Marilia B., Rathmann, Wolfgang, Shimomura, Iichiro, Vora, Jiten, Watada, Hirotaka, Khunti, Kamlesh et al. · 2022 · BMC Endocrine Disorders
66. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó, Rafael, Hernández, Cristina · 2017 · Diabetes
67. Proteomic changes upon treatment with semaglutide in individuals with obesity
    Maretty, Lasse, Gill, Dipender, Simonsen, Lotte, Soh, Keng, Zagkos, Loukas, Galanakis, Michael, Sibbesen, Jonas, Iglesias, Miquel Triana, Secher, Anna, Valkenborg, Dirk et al. · 2025 · Nature Medicine
68. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
    Kasia J. Lipska, Harlan M. Krumholz · 2017 · JAMA
69. Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016
    Albert Lecube, Susana Monereo, Miguel Ángel Rubio, Purificación Martínez de Icaya, Amelia Martí, Javier Salvador, Lluís Masmiquel, Albert Goday, Diego Bellido, Empar Lurbe et al. · 2016 · Endocrinología Diabetes y Nutrición
70. Novel Diabetes Drugs and the Cardiovascular Specialist
    Naveed A. Sattar, Mark Colquhoun Petrie, Bernard Zinman, James L. Januzzi · 2017 · Journal of the American College of Cardiology
71. Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
    John Dennis, William Henley, Andrew Peter McGovern, Andrew A. Farmer, Naveed A. Sattar, Rury R. Holman, Ewan R. Pearson, Andrew Tym Hattersley, Beverley M. Shields, Angus G. Jones · 2019 · Diabetes Obesity and Metabolism
72. Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output
    Junling Liu, Kun Yang, Jin Yang, Wenhua Xiao, Yunyi Le, Fei Yu, Liangbiao Gu, Shan Lang, Qing Tian, Tianru Jin et al. · 2019 · EBioMedicine
73. Leveraging the Gut to Treat Metabolic Disease
    Ruth E. Gimeno, Daniel A. Briere, Randy J. Seeley · 2020 · Cell Metabolism
74. Clinical approach to the inflammatory etiology of cardiovascular diseases
    Massimiliano Ruscica, Alberto Corsini, Nicola Ferri, Maciej Banach, Cesare Riccardo Sirtori · 2020 · Pharmacological Research
75. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
    Francesco Giorgino, Jiten P Vora, Peter Fenici, Anna Solini · 2020 · Cardiovascular Diabetology
76. Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
    S. Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, Umme Rubab, Prathap Kanagala, Sizheng Steven Zhao, Anne Worthington, Emily E. Brown, Uazman Alam · 2022 · Clinical Therapeutics
77. Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
    McLean, Brent A., Wong, Chi Kin, Kaur, Kiran Deep, Seeley, Randy J., Drucker, Daniel J. · 2021 · JCI Insight
78. Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
    Thomas Nyström, Johan Bodegård, David Nathanson, Marcus Thuresson, Anna Norhammar, Jan W. Eriksson · 2017 · Diabetes Obesity and Metabolism
79. Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records
    Elisabetta Patorno, Chandrasekar Gopalakrishnan, Jessica Myers Franklin, Kimberly Goodnow Brodovicz, Elvira L Massó-González, Dorothee B. Bartels, Jun Liu, Sebastian Schneeweiß · 2017 · Diabetes Obesity and Metabolism
80. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients
    Singh, Priyamvada, Pesavento, Todd E., Washburn, Kenneth, Walsh, Debbie, Meng, Shumei · 2019 · Diabetes Obesity and Metabolism
81. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis
    Lana Catani Ferreira Pinto, Mariana Rangel Ribeiro Falcetta, Dimitris Rucks Varvaki Rados, Cristiane Bauermann Leitão, Jorge Luiz Gross · 2019 · Scientific Reports
82. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
    Besmir Nreu, Ilaria Dicembrini, Federico Tinti, Giorgio Sesti, Edoardo Mannucci, Matteo Monami · 2020 · Nutrition Metabolism and Cardiovascular Diseases
83. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
    Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lorenzo Gubian, Angelo Avogaro, Gian Paolo Fadini · 2020 · BMJ Open Diabetes Research & Care
84. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis
    Li Chunxing, Shuo Liang, Lingyan Gao, Hua Liu · 2021 · PLoS ONE
85. Management of diabetes in older adults
    Giorgio Sesti, Raffaele Antonelli Incalzi, Enzo Bonora, Agostino Consoli, Andrea Giaccari, Stefania Maggi, Giuseppe Paolisso, Francesco Purrello, Gianluigi Vendemiale, Nicola Ferrara · 2017 · Nutrition Metabolism and Cardiovascular Diseases
86. GLP‐1 receptor agonist added to insulin versus basal‐plus or basal‐bolus insulin therapy in type 2 diabetes: A systematic review and meta‐analysis
    Castellana, Marco, Cignarelli, Angelo, Brescia, Francesco, Laviola, Luigi, Giorgino, Francesco · 2019 · Diabetes/Metabolism Research and Reviews
87. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis
    Bellastella, Giuseppe, Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario · 2020 · Stroke
88. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
    Gillian L. Booth, Lorraine Lucille Lipscombe, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Ronald Goldenberg, Nadia Khan, Lori MacCallum, Baiju R. Shah, Scot H. Simpson et al. · 2016 · Canadian Journal of Diabetes
89. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
    Julio Rosenstock, Vlado Perkovic, John Hunter Alexander, Mark Emmanuel Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra et al. · 2018 · Cardiovascular Diabetology
90. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
    Paneni, Francesco, Lüscher, Thomas F. · 2017 · The American Journal of Cardiology
91. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
    Anniek Frederike Lubberding, Simon Veedfald, Jonathan Samuel Achter, Sarah Dalgas Nissen, Luca Soattin, Andrea Sorrentino, Estefanía Torres-Vega, Benedikt M. Linz, Caroline Eggert Eggertsen, John F. Mulvey et al. · 2024 · Cardiovascular Research
92. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management
    Aikaterini Eleftheriadou, Vincenza Spallone, Abd A. Tahrani, Uazman Alam · 2024 · Diabetologia
93. Endothelial glycocalyx
    Foote, Christopher A., Soares, Rogerio N., Ramirez‐Perez, Francisco I., Ghiarone, Thaysa, Aroor, Annayya, Manrique‐Acevedo, Camila, Padilla, Jaume, Martinez‐Lemus, Luis · 2022 · Comprehensive Physiology
94. Diabetes-related cardiomyopathy: the sweet story of glucose overload from epidemiology to cellular pathways
    Joubert, M., Manrique, A., Cariou, B., Prieur, X. · 2019 · Diabetes & Metabolism
95. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
    Garg, Vinay, Verma, Subodh, Connelly, Kim · 2019 · Progress in Cardiovascular Diseases
96. Cardiovascular outcome trials of glucose-lowering medications: an update
    Philip D. Home · 2019 · Diabetologia
97. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
    Salvatore Carbone, Dave L. Dixon · 2019 · Cardiovascular Diabetology
98. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
    Giovana Fagundes Piccoli, Leonardo A Mesquita, Cinara Stein, Marina Meneses Aziz, Maira Zoldan, Nathália Abi Habib Degobi, Bernardo Frison Spiazzi, Gilberto L Lopes Junior, Verônica Colpani, Fernando Gerchman · 2020 · The Journal of Clinical Endocrinology & Metabolism
99. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
    Min Zhao, Shusen Sun, Zhenguang Huang, Tiansheng Wang, Huilin Tang · 2020 · Clinical Journal of the American Society of Nephrology
100. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
     Gallwitz, Baptist · 2022 · Frontiers in Endocrinology